Literature DB >> 25006741

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

Bruno Cassinat1, Emmanuelle Verger, Jean-Jacques Kiladjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25006741     DOI： 10.1056/NEJMc1401255

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

2.  2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.

Authors:  Jan Jacques Michiels; Mihaela Tevet; Adrian Trifa; Emilia Niculescu-Mizil; Anca Lupu; Ana Maria Vladareanu; Horia Bumbea; Anca Ilea; Camelia Dobrea; Daniela Georgescu; Oana Patrinoiu; Mihaela Popescu; Meilin Murat; Cornel Dragan; Felicia Mihai; Sabina Zurac; Silvana Angelescu; Anamaria Iova; Alina Popa; Rodica Gogulescu; Violeta Popov
Journal:  Maedica (Bucur)       Date:  2016-03

Review 3.  Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Omar Abdel-Wahab; Raajit Rampal; Ruben Mesa; Steffen Koschmieder; Ross Levine; Rüdiger Hehlmann; Giuseppe Saglio; Tiziano Barbui; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2016-05-31

Review 4.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

5.  Central role of ULK1 in type I interferon signaling.

Authors:  Diana Saleiro; Swarna Mehrotra; Barbara Kroczynska; Elspeth M Beauchamp; Pawel Lisowski; Beata Majchrzak-Kita; Tushar D Bhagat; Brady L Stein; Brandon McMahon; Jessica K Altman; Ewa M Kosciuczuk; Darren P Baker; Chunfa Jie; Nadereh Jafari; Craig B Thompson; Ross L Levine; Eleanor N Fish; Amit K Verma; Leonidas C Platanias
Journal:  Cell Rep       Date:  2015-04-16       Impact factor: 9.423

Review 6.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 7.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

8.  A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.

Authors:  Yining Yang; Xiaorui Wang; Chun Wang; Youwen Qin
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

9.  Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis.

Authors:  Wenjing Gu; Renchi Yang; Zhijian Xiao; Lei Zhang
Journal:  Int J Hematol       Date:  2021-06-06       Impact factor: 2.490

10.  The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Authors:  M O Holmström; E Martinenaite; S M Ahmad; Ö Met; C Friese; L Kjær; C H Riley; P Thor Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2017-07-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.